Douglas Stewart

10PUBLICATIONS
20CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersBiologically active moleculesMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 27, 2025
Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial.

Arjun Pandey, Kim Roos, Yidi Jiang

|May 27, 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.

Douglas A Stewart, John Kuruvilla, David Lee

|May 09, 2023
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.

Irina Amitai, Kim Roos, Iran Rashedi

|Aug 26, 2021
Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic.

Tom Dunne, Douglas Stewart, Holly Lee

|Mar 12, 2021
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.

Farheen Manji, Robert Puckrin, Douglas A Stewart

|Jun 11, 2020
Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy.

Jiajia Liu, Douglas Stewart, Amelie Fontaine

Pageof 2

Frequent Collaborators

2 joint publications

Anthea Peters

2 joint publications

Neil L Berinstein

1 joint publications

Mita Manna

1 joint publications

Richard Lee-Ying